HilleVax (HLVX) Competitors

Voyager Therapeutics (NASDAQ:VYGR) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Does the media prefer VYGR or HLVX?

In the previous week, Voyager Therapeutics had 16 more articles in the media than HilleVax. MarketBeat recorded 25 mentions for Voyager Therapeutics and 9 mentions for HilleVax. Voyager Therapeutics' average media sentiment score of 0.36 beat HilleVax's score of -0.37 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
HilleVax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more risk and volatility, VYGR or HLVX?

Voyager Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Is VYGR or HLVX more profitable?

Voyager Therapeutics has a net margin of 15.80% compared to HilleVax's net margin of 0.00%. Voyager Therapeutics' return on equity of 8.51% beat HilleVax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	15.80%	8.51%	6.18%
HilleVax	N/A	-67.27%	-51.99%

Which has preferable earnings and valuation, VYGR or HLVX?

Voyager Therapeutics has higher revenue and earnings than HilleVax. HilleVax is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$143.77M	2.36	$132.33M	$0.71	8.76
HilleVax	N/A	N/A	-$123.57M	-$3.10	-0.61

Do institutionals & insiders have more ownership in VYGR or HLVX?

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 71.1% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend VYGR or HLVX?

Voyager Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 173.31%. HilleVax has a consensus price target of $9.20, suggesting a potential upside of 386.77%. Given HilleVax's higher possible upside, analysts clearly believe HilleVax is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
HilleVax	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor VYGR or HLVX?

Voyager Therapeutics received 379 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 67.53% of users gave Voyager Therapeutics an outperform vote while only 58.82% of users gave HilleVax an outperform vote.

Company	Underperform	Outperform
Voyager Therapeutics	Outperform Votes 389 67.53%	Underperform Votes 187 32.47%
HilleVax	Outperform Votes 10 58.82%	Underperform Votes 7 41.18%

Summary

Voyager Therapeutics beats HilleVax on 15 of the 18 factors compared between the two stocks.